Relatively Speaking
Controlling Polysorbate Degradation
Accelerating Cross-Sector Integration in Pharma and Nutraceuticals
From the “AI Pilot Graveyard” to Enterprise- Grade Impact
Cloud-Native Drug Discovery
EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
.webp)
KNOWLEDGE BANK
-
Articles
Adaptive Trial Designs: Enhancing Speed and Decision-Making in Clinical Development
For decades the traditional clinical trial has followed a rigid script A protocol is written patients are enrolled the study runs to completion and only at the very end does the sponsor learn whether the investment paid off The model has served the industry well in terms of scientific rigour
B2B Lead Generation Pharma: High-ROI Tactics for European Markets
The European pharmaceutical industry can be called one of the most complicated and highly regulated markets in the world In the global market where a centralized approval system under the oversight of the European Medicines Agency EMA is required to the reimbursement systems specific to each country in Germany France Italy Spain and the Nordics market entry and market growth needs the accuracy of...
Why Leading Pharma Professionals Rely on the Pharma Focus Europe E-Newsletter
The network of the pharmaceutical and life sciences in Europe is undergoing a radical transformation There are changes in the regulatory environments a rise in the pace of innovation a shift in leadership and a change in the distribution production and development of therapies by the use of digital technologies In this environment no longer will access to timely credible and context rich informati...
Pharmaceutical Quality Management in Europe: GMP Systems, Quality Control and Manufacturing Standards
A tablet that works in a lab means little if the next batch is slightly different Pharmaceutical quality management exists to make sure every pack in every pharmacy matches the one that was tested and approved In Europe that promise is backed by one of the most mature regulatory frameworks in the world Whether you run a small contract manufacturer in Ireland or a large sterile plant in Germany EU...
Beyond GLP-1: Emerging Biologic Therapies Reshaping Chronic Disease Care
For most of this decade one drug class has dominated boardroom conversations about chronic disease Its commercial force needs no further retelling Its deeper legacy is easier to miss it taught health systems and patients to expect that a longterm condition could be altered by a wellengineered injection and then forced
EU Pharma Reform 2025 Explained: What Market Access Leaders Must Know for 2026-2029
What if your EU market exclusivity depends on launching your medicine in every member state and proving its realworld value This is no longer hypothetical The historic Pharma Reform agreement of the Council of the EU of March is the first major revision of pharmaceutical legislation in more than years It will have a significant impact on the way businesses will enter the market set their prices...
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
B2B Lead Generation Pharma: High-ROI Tactics for European Markets
Kate Williamson
The pharmaceutical industry in Europe is changing due to regulatory pressures, the acceleration of the digital industry, and value-based care models. In case of B2B pharma marketer, lead generation sh...
-
2
-
3
Pharmaceutical Quality Management in Europe: GMP Systems, Quality Control and Manufacturing Standards
Sarah Richards
European pharmaceutical quality rests on EU GMP, a risk-based quality system and rigorous quality control. This article explains how EudraLex Volume 4, Qualified Persons, data integrity and Annex 1 sh...
-
4
Beyond GLP-1: Emerging Biologic Therapies Reshaping Chronic Disease Care
Lakshmi
Chronic disease care is moving beyond a single drug class. Ultra-long-acting antibodies, amylin-based therapies and upstream immune blockers are changing what counts as value, while a failed cardiovas...
-
5
EU Pharma Reform 2025 Explained: What Market Access Leaders Must Know for 2026-2029
No Author
The EU Pharma Reform is reshaping the pharmaceutical landscape across Europe. Following the Council of the EU's landmark March 2024 agreement, this article decodes the shift from fixed-term regula...
press releases Read more...
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
NervGen NASDAQ NGEN a latestage clinical biopharmaceutical company developing firstinclass neuroreparative therapeutics for spinal cord injury SCI and other neurotraumatic and neurologic conditions today announced
Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease
Lineage Cell Therapeutics Inc NYSE American and TASE LCTX a clinicalstage biotechnology company developing allogeneic off the shelf cell therapies for serious medical conditions today announced that the Company has acquired NeuroAirmid
Instem and Sable Bio Launch Partnership to Accelerate Target Risk Assessment Through AI-Powered Scientific Intelligence
Instem a leading provider of software solutions and scientific services for drug discovery and development today announced a strategic partnership with Sable Bio to transform how biopharmaceutical organizations evaluate target safety and risk
Laboratoires Pierre Fabre and XtalPi Announce an AI-Driven Collaboration Focused on Drug Discovery
Laboratoires Pierre Fabre and XtalPi are pleased to announce an agreement under which they will collaborate on the discovery of novel clinical candidates across a number of research programs in the field of oncology potentially dermatology and rare diseases
Events Read more...
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
25 - 25
Nov 2026What’s Next for Pharma Marketing in 2027
Landesmuseum Zürich, Zurich, S...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
LATEST NEWS Read more...
Immuneering and Astellas to Evaluate Combination Treatments for CLDN18.2-Expressing Pancreatic Cancer
Immuneering Corporation Nasdaq IMRX has entered into a clinical trial collaboration and supply agreement with Astellas Pharma Global Development Inc a subsidiary of Astellas Pharma Inc TSE to evaluate combination treatments for patients with pancreatic cancer whose tumours express CLDN
Takeda Launches ORZEYFUL (Oveporexton), the First Orexin Agonist for Narcolepsy Type 1, in the US
Takeda TSE NYSE TAK has announced the US launch of ORZEYFUL oveporexton CIV now available by prescription for adults with narcolepsy type NT also known as narcolepsy with cataplexy The medicine is the first and only orexin agonist available for this condition
Applied Biologics Partners with Dartmouth College on Computational Protein Engineering Research
Applied Biologics a biopharmaceutical company developing biologic and gene therapies for serious diseases has entered into a research collaboration agreement with Dartmouth Colleges Thayer School of Engineering
Onco-Innovations Agrees to Terminate Performance-Based Funding Arrangement with Sorbie
OncoInnovations Limited Cboe ONCO has entered into an agreement with Sorbie Bornholm LP SBLP and Sorbie Investments LLP SILP to terminate its previously announced performancebased funding arrangement which was disclosed on July
Oncovita Granted Orphan Drug Designation For MVdeltaC in Mesothelioma by the European Commission
Oncovita a French biotechnology company specialized in therapeutic and prophylactic vaccines today announced that the European Commission has granted orphan medicinal product designation to its lead investigational candidate MVdeltaC for the treatment of mesothelioma
DeepLife and 3billion partner to discover small-molecule therapeutics against genetic modifier targets across multiple diseases
DeepLife a Parisbased techbio company developing AIpowered digital twins of human cells and billion an AIpowered genomics company specializing in rare disease diagnostics and drug discovery today announced a codevelopment collaboration to discover and develop new smallmolecule therapeutics
